HOYA Japanese personnel are safe

Article

HOYA Surgical Optics do not expect any disruption to their deliveries and business following the recent earthquakes and tsunami in Japan.

HOYA Surgical Optics do not expect any disruption to their deliveries and business following the recent earthquakes and tsunami in Japan.

A statement, released by the global optic solutions provider, also expresses the firm's sympathy and concern following the events in their native country.

HOYA colleagues have been relieved to learn that employees working in the medical field have not been seriously injured or missing. They have also show their appreciation of individuals who have enquired about the well being of HOYA's personnel located in Japan. HOYA wish a rapid recovery to the citizens of Japan.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.